Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs BTP 114 (Primary)
- Indications Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Placon Therapeutics
- 28 Oct 2016 Status changed from planning to recruiting.
- 30 Mar 2016 New trial record
- 23 Mar 2016 According to a Placon Therapeutics media release, the US FDA has accepted an Investigational New Drug (IND) application of BTP-114 to begin clinical evaluation in cancer patients.